What has been accomplished in COVID-19 era by REMAP-CAP

Steve Webb
Australian and New Zealand Intensive Care Research Centre, Monash University, Australia

REMAP-CAP is a global adaptive platform trial for patients with severe Community Acquired Pneumonia that adapted in early 2020 to evaluate candidate interventions for severe COVID-19 infection. Japan is not contributing to REMAP-CAP. The platform has expanded to recruit in more than 300 hospitals in 24 countries. The platform has several design features that contribute to its capacity to generate evidence of treatment effect for multiple treatments. Treatment effect has been reported for ten candidate treatments including reporting beneficial impact for corticosteroids, interleukin-6 receptor antagonists, and prophylactic therapeutic anticoagulation in non-critically ill patients as well as reporting lack of beneficial treatment effect for selected antiviral agents, convalescent plasma, antiplatelet agents, and prophylactic therapeutic anticoagulation in critically ill patients.